The clinical usefulness of CCK as an anti-obesity, appetite reducing agent was found, however, to be transient due to the development of tolerance to CCK and its analogs (43)
Ni Lochlainn M, Bowyer RCE, Moll JM, Garcia MP, Wadge S, Baleanu AF, Nessa A, Sheedy A, Akdag G, Hart D, et al
A 2025 Bayesian network meta-analysis placed retatrutide in comparative context against mono-agonists and dual agonists for weight-loss outcomes in non-diabetic populations (PMID 40685589)
See Table 3 in the Appendix for further details on ICD- and ATC-codes
It requires extensive Phase 3 trials before an FDA application can be submitted, meaning approval is likely several years away (estimates point to 20262027 at the earliest)
Across repeated weekly doses the drug accumulates to a steady state, so trough levels hold high enough to maintain therapeutic effect, without a cliff-like drop before the next dose